Background: Colistin (polymyxin E) is active against multidrug-resistant Gram-negative bacteria (MDR-GNB). However, the effectiveness of inhaled colistin is unclear. This study was designed to assess the effectiveness and safety of aerosolized colistin for the treatment of ventilator-associated pneumonia (VAP) caused by MDR-GNB. Methods: In this retrospective longitudinal study, we evaluated the medical records of 63 patients who received aerosolized colistin treatment for VAP caused by MDR-GNB in the medical intensive care unit (MICU) from February 2012 to March 2014. Results: A total of 25 patients with VAP caused by MDR-GNB were included in this study. The negative conversion rate was 84.6% after treatment, and acute kidney injury (AKI) occurred in 11 patients (44%, AKI group). The average length of MICU stay and colistin treatment-related factors, such as daily and total cumulative doses and administration period, were not significantly different between groups. In-hospital mortality tended to be higher in the AKI group (p = 0.07). Multivariate analysis showed that a body mass index less than 18 was an independent risk factor of mortality (odds ratio [OR] = 21.95, 95% confidence interval [CI] 1.59-302.23; p = 0.02). Notably, AKI occurrence was closely related to the administration of more than two nephrotoxic drugs combined with aerosolized colistin (OR = 15.03, 95% CI 1.40-161.76; p = 0.025) and septic shock (OR = 8.10, 95% CI 1.40-161.76; p = 0.04).
Introduction
Colistin (Polymyxin E) is an antibiotic whose mode-of-action changes the structure of phospholipids in bacterial cell membranes. [1] After its discovery in the 1940s from Bacillus polymyxa, colistin was commonly used to treat Gramnegative bacterial infections up until the early 1980s. [2] In spite of its excellent bactericidal efficacy, colistin has been replaced by new antibiotics, and its use has largely decreased due to a 50% rate of serious nephrotoxicity and neurotoxicity associated with intravenous administration. (MDR-GNB), particularly Pseudomonas aeruginosa and Acinetobacter baumannii. Because these bacteria are highly susceptible to colistin, its use has again increased. [2] A number of recent studies on colistin indicate that its neurotoxicity has decreased and have failed to identify a clear association between colistin treatment and neurotoxic events. However, the incidence of nephrotoxicity is still high, ranging from 8-45%. [2] [3] [4] Additionally, its low penetration into infected tissues is a potential obstacle for intravenous injection. [3] [4] [5] [6] A previous study demonstrated that aerosolized colistin treatment was effective for treating cystic fibrosis patients with chronic P. aeruginosa lung infections. [7] Furthermore, favorable results for aerosolized colistin treatment have been reported in patients with ventilator-associated pneumonia (VAP), [8] including a lower incidence of nephrotoxicity with aerosol treatment than with intravenous injection.
Nonetheless, in these studies, nephrotoxicity was still frequent (15-32%). [9, 10] Critically, research on the relationship between daily and cumulative colistin doses and the incidence of nephrotoxicity with aerosolized colistin treatment has been limited, [11, 12] The purpose of this study was to clarify the effectiveness, safety profiles, and the incidence and related risk factors of inhaled colistinassociated nephrotoxicity in patients with VAP caused by MDR-GNB.
Materials and Methods

1) Study design and data collection
The data were obtained retrospectively from medical records of patients who received aerosolized colistin treatment for VAP caused by MDR-GNB in the medical intensive care unit (MICU) at Chonbuk National Univer- and procalcitonin (PCT) were obtained just before and at the completion of treatment. These measures were used to assess any adverse drug reactions, as well as to determine the efficacy of aerosolized colistin treatment.
2) Definitions
Pneumonia was considered to be ventilator-associated if the onset occurred after 48 hours of intubation and if the infection was determined to be absent before the initiation of mechanical ventilation. The severity of the clinical condition at the time of VAP diagnosis was assessed according to APACHE II [15] and clinical pulmonary infection scores. [16] Response to treatment was assessed at the end of antimicrobial therapy. Negative conversion was defined "no growth of the pathogen," and persistence was defined as continuous growth of the responsible pathogen regardless of the clinical outcome of the infection. [17] In patients with normal renal function, nephrotoxicity was defined as serum creatinine > 2 mg/dL or a 50% reduction in the automatically estimated glomerular filtration rate (eGFR) using the Chronic Kidney Disease Epidemiology Collaboration equation formula (CKD-EPI) [18] compared to the value at the start of treatment or a decline in renal function that prompted renal replacement therapy. In patients with preexisting renal dysfunction, nephrotoxicity was defined as an increase > 50% of the baseline creatinine level or as a 50% reduction in the eGFR by CKD-EPI relative to the value at therapy initiation, according to risk, injury, failure, loss of kidney function, and end-stage renal failure (RIFLE) criteria. [19] 3) Aerosolized colistin treatment
The aerosolized colistin used in this study was Coly- 
4) Outcome measures
To determine the effectiveness of aerosolized colistin treatment for MDR-GNB pneumonia, we evaluated the length of MICU stay, mortality, mechanical ventilation day, and the microbiological outcome. The incidence and potential risk factors of nephrotoxicity and the occurrence of adverse events related to aerosolized colistin treatment were also evaluated. All potential adverse effects related to aerosolized colistin use, such as bronchoconstriction, cough, apnea, chest tightness, and arterial hypoxemia were reviewed.
5) Statistical analysis
Analyses were performed with IBM SPSS Statistics software, version 18.0 (IBM Co., Armonk, NY, USA).
Categorical variables are presented as frequency and
percentage, and these were verified by the Chi-square test. Continuous variables are expressed as mean ± standard deviation (SD) and verified by either the paired or unpaired Student's t-test. To identify the risk factors of nephrotoxicity in aerosolized colistin treatment, the relationship between concomitant nephrotoxic drug use and the occurrence of acute kidney injury (AKI) was verified using Fisher's exact probability test. A p-value < 0.05 was considered to be significant. Univariate and multivariate analyses of risk factors associated with aerosolized colistin-induced nephrotoxicity and mortality during treatment were performed using logistic regression mod-els. Variables that emerged from the univariate analysis with significant p-values were candidates for inclusion in the multivariate analysis.
Results
1) Clinical characteristics of subjects and microbiological etiology
A total 25 patients were underwent aerosolized colistin treatment for MDR-GNB VAP in the study period and finally analyzed ( 
2) Microbiologic outcomes
The microbiological etiologies of VAP were predominantly found to be A. baumannii (22 day vs. 16.0 ± 7.5 day, p = 0.805) between negative conversion and non-conversion patients.
3) Clinical outcomes
The mean length of MICU stay was 30. (Fig. 2) .
Notably, aerosolized colistin-associated AKI does not seem to have an effect on the mortality (OR = 0.33, 95% CI 0.06-1.75; p = 0.19) ( Table 3 ).
Both the leukocyte count and PCT level decreased after treatment with aerosolized colistin, although these decreases were not significant. However, the level of hs-CRP was significantly decreased after aerosolized colistin treatment (Table 4) .
4) Demographic and laboratory findings in AKI and non-AKI groups
Eleven of the 25 patients (44.0%) who underwent aerosolized colistin treatment exhibited AKI according to the RIFLE criteria; one patient (9.1%) was in the risk group, six patients (54.5%) were in the injury group, and four patients (36.4%) were in the failure group. The eGFR based on CKD-EPI of the AKI group was nearly half that of the non-AKI group (45.9 ± 24.2 vs. 86.3 ± 45.3, respectively p = 0.01) ( Table 5 ).
The cumulative dose and time interval from aerosolized colistin administration to the onset of AKI were 
5) Predictors of aerosolized colistin treatment-associat-
ed AKI
Multivariate analysis showed that septic shock was an independent risk factor of AKI (OR = 8.10, 95% CI 1.23- (Table 6 ).
Discussion
The highlight of the presents study was that negative conversion rate of inhaled colistin was more than 80% in patients with MDR-GNB VAP. And the incidence of AKI defined by RIFLE criteria was 44% of inhaled colistin treatment patients. Finally, septic shock and more than two nephrotoxic drugs combined with aerosolized colistin were independent risk factors of AKI.
The low tissue penetration rate and high nephrotoxicity of intravenous colistin treatment has led to its use as an aerosol treatment in patients with cystic fibrosis and VAP. [23] In this study, we observed an 84.6% bacterial negative conversion rate after aerosolized colistin treatment. Leukocyte count and PCT level decreased after treatment, but not significantly so. However, the level of hs-CRP measured after treatment was significantly lower than those observed before treatment.
Our study also offers insight into the tissue penetration and optimal dosage for aerosolized colistin. It is estimated that only 60% of each dose is inhaled into the bronchi, as some of the drug remains in the nebulizer. Therefore, a previous study recommended a dose of 150 mg colistin base activity three times per day (450 mg daily) for aerosol treatment. [24] However, nebulizer types and techniques, including ventilator settings, also affect aerosol distribution to the lungs. [24] In our study, a daily dosage of 300 mg colistin base activity was administered in 2-4 doses daily using an ultrasonic nebulizer with ventilator settings. [25] This was found to provide effective aerosol therapy, as evidenced by our high negative conversion rate. [17] A previous study on aerosolized colistin reported a reduced incidence of nephrotoxicity for this mode of treatment compared to intravenous injection. [6] However, based on the RIFLE criteria, we observed AKI in 44% of our subjects (11 patients). This dissimilar incidence of colistin-related nephrotoxicity in the two studies could be resulted by the differences in the definitions of nephrotoxicity, dosing schedules, or duration of treatment. In other studies that have used the RIFLE criteria, colistin- related nephrotoxicity was observed in up to 49% of patients; [26] in another study, it was closely associated with the total dose and treatment duration of colistin. [11] However, in our study, the daily dose, cumulative dose, and period of administration did not differ between the AKI and non-AKI groups, and none of these were predictors of AKI. The dose and administration schedules of aerosolized colistin were repeatedly adjusted by renal function based on the drug package insert, [19, 21] using eGFR [22] in the morning and evening and hourly urine output. As a result, colistin dose and administration intervals were adjusted very strictly. In addition, the administration route itself could be an important predictive factor of AKI. Inhalation is theoretically appealing, as aerosolized local delivery to the lungs should avoid, or at least minimize, potential renal toxicity compared to systemic administration (~45% vs. ~32%, respectively). [3, 10] Most patients in the MICU are treated with multiple medications at the same time. In our study, all patients in the AKI group were concomitantly administered more than one potentially nephrotoxic medication, and receiving more than two nephrotoxic medications was predictive of renal toxicity. Thus, the concomitant use of nephrotoxic medications seems to be more influential to the development of nephrotoxicity than monotherapy with aerosolized colistin. Therefore, renal function such as eGFR must be monitored regularly when colistin is administered with other drugs that have nephrotoxic potential.
Several factors such as BMI < 18 kg/m 2 and concomitant administration of aminoglycosides or amphotericin B were correlated with significantly higher mortality ( Table 2 ). The obesity is closely associated with many medical problems such as diabetes, cardiovascular and respiratory diseases, and cancers. [27] The impact of obesity on outcome in critically ill patients has not been conclusive yet, the mortality in obese and very obese patients with septic shock seems to be lower than normal weight patients. [28] [29] [30] This absurd phenomenon is called the "obesity paradox". [30] In our study, only BMI < 18 kg/m 2 was a unique independent risk factor of mortality in multivariate analysis (OR = 21.95, 95% CI 1.59-302.23; p = 0.020).
The use of aerosolized antibiotics can be accompanied by other adverse effects, including chest symptoms (e.g., cough, wheezing, and dyspnea) and pharyngolaryngitis.
Because the aerosolized formulation of colistin has not yet been developed, the intravenous vial formulation of colistin is converted for aerosol use in clinical practice.
Therefore, these intravenous vials contain preservatives, and some patients with asthma or sensitive bronchi have reported decreased forced expiratory volume and bronchospasm when this formulation was used for aerosol treatment. [31] In this study, a bronchodilator, such as a β 2 adrenergic agonist and/or anticholinergic agent, was used 20 minutes before treatment to prevent bronchospasm.
Nevertheless, one patient showed severe bronchospasm, followed by decreased blood pressure. This patient was thereafter given intravenous colistin instead of aerosolized treatment. No other colistin-related toxicities, such as neurotoxicity or muscular weakness, were observed.
Despite its merit and the plausible research question, this paper is flawed by its retrospective design and the small number of patients enrolled. Furthermore, the lack of a control group who did not receive aerosolized colistin limited the evaluation of the true effect. Finally, the concentrations of colistin in the bronchial and alveolar tissues and blood were not measured after treatment.
In this study, 84.6% of MDR-GNB pneumonia patients showed negative conversion after aerosolized colistin treatment, and inflammation-associated hs-CRP level improved. Although 44% of patients exhibited signs of nephrotoxicity, this effect was likely due to concomitant treatment with other nephrotoxic medications, rather than colistin monotherapy. These limits clearly jeopardize the solidity of the final conclusions. Therefore, further studies on the optimal dose of colistin should be conducted to minimize nephrotoxicity and effectively treat patients with pulmonary infection.
In conclusion, adjunctive aerosolized colistin treatment might be an effective and relatively safe option to eradicate MDR-GNB in patients with pneumonia. However, renal function should be monitored regularly to reduce the incidence of aerosolized colistin-induced nephrotoxicity when colistin is administered concomitantly with potentially nephrotoxic drugs.
